Nilda Mesa Sells 228 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 228 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $505.87, for a total value of $115,338.36. Following the sale, the director owned 5,580 shares of the company’s stock, valued at $2,822,754.60. The trade was a 3.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $2.35 during midday trading on Tuesday, hitting $500.35. The company’s stock had a trading volume of 1,326,943 shares, compared to its average volume of 496,432. The business’s 50 day simple moving average is $520.02 and its 200 day simple moving average is $540.96. United Therapeutics Corporation has a 12-month low of $397.00 and a 12-month high of $609.35. The company has a market cap of $21.46 billion, a P/E ratio of 17.90, a price-to-earnings-growth ratio of 2.49 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business earned $6.41 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on UTHR. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Morgan Stanley set a $515.00 price target on United Therapeutics in a report on Thursday, August 6th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Bank of America dropped their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC purchased a new position in United Therapeutics in the 2nd quarter worth approximately $450,140,000. Norges Bank purchased a new position in shares of United Therapeutics in the fourth quarter valued at $293,418,000. Bank of New York Mellon Corp acquired a new stake in shares of United Therapeutics during the second quarter valued at about $159,522,000. Finally, Caisse de depot et placement du Quebec purchased a new stake in United Therapeutics during the 2nd quarter worth approximately $154,304,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.